Table 1.
Summary of results from systematic reviews and meta-analyses evaluating the risk of cardiovascular disease in patients with psoriasis and psoriatic arthritis.
| Study Number | Study Population | Identified Risk Among CV Conditions |
The Relative Risk of Measures |
|---|---|---|---|
| Psoriasis | |||
| 1 [14] | Psoriasis patients: 503,686 Controls: 29,686,694 |
CVD, IHD, cerebrovascular disease, and CV mortality |
CVD in total OR 1.4 (1.2–1.7) IHD OR 1.5 (1.2–1.9) Cerebrovascular disease OR 1.1 (0.9–1.3) CV mortality OR 0.9 (0.4–2.2) |
| 2 [15] | Psoriasis patients + controls: 6,230,774 |
Stroke, MI, CVD, and CV mortality |
Stroke RR 1.26 (1.12–1.41) MI RR 1.32 (1.13–1.55) CVD RR 1.47 (1.30–1.60) CV mortality RR 1.33 (1.00–1.77) |
| 3 [16] | Psoriasis patients: 324,650 Controls: 5,309,087 |
MI, CAD, and stroke | Cohort studies: MI OR 1.25 (1.03–1.52), CAD OR 1.20 (1.13–1.27), stroke OR 1.02 (0.92–1.14) Cross-sectional studies: MI OR 1.57 (1.08–2.27), CAD OR 1.84 (1.09 –3.09), stroke OR 1.14 (1.08–1.19) |
| 4 [17] | Psoriasis patients: 367,358 Controls: 9,199,656 |
CV events: MI, IHD, cerebral ischemic stroke, and sudden cardiac death |
CV events OR 1.28 (1.18–1.38) |
| 5 [18] | Psoriasis patients: 488,315 (mild: 327,418; severe: 12,854) Controls: 10,024,815 |
CVD mortality, MI, and Stroke |
All psoriasis: MI HR 1.40 (1.03–1.89) and stroke HR 1.13 (1.01–1.26) Mild psoriasis: CVD mortality SMR 1.03 (0.86–1.25), MI HR 1.34 (1.07– 1.68), and stroke HR 1.15 (0.98–1.35) Severe psoriasis: CVD mortality SMR 1.37 (1.17–1.60), CVD mortality HR 1.57 (1.26–1.96), MI HR 3.04 (0.65–14.35) and stroke HR 1.59 (1.34– 1.89) |
| 6 [19] | Psoriasis patients: 218,654 (mild: 201,239; severe: 17,415) Controls: 9,914,799 |
MACE: CV mortality, MI, and stroke |
Mild Psoriasis: MI RR 1.29 (1.02–1.63), stroke RR 1.12 (1.08–1.16) Severe Psoriasis: MI RR 1.70 (1.32–2.18), stroke RR 1.56 (1.32–1.84), CV mortality RR 1.39 (1.11–1.74) |
| 7 [20] | Psoriasis patients: 1,862,297 Controls: 43,407,300 |
MI, CVD, and CV death | Overall CV RR 1.24 (1.18–1.31), MI RR 1.24 (1.11–1.39) Vascular disease RR 1.27 (1.12–1.43), CV Mortality RR 1.41 (0.97–2.04) |
| 8 [21] | Psoriasis patients: 326,598 Controls: 5,230,048 |
MI, and stroke | MI and stroke RR 1.20 (1.10–1.31) MI RR 1.22 (1.05–1.42) Stroke RR 1.21 (1.04–1.40) |
| Psoriatic arthritis | |||
| 1 [23] | Psoriatic arthritis patients: 32,973 Controls: 4,568,723 |
CVD, CV events Morbidity risks for MI, cerebrovascular events, and heart failure |
CVD OR 1.43 (1.24–1.66) CV events 1.55 (1.22–1.96) Morbidity risk for MI OR 1.68 (1.31–2.15) Morbidity risk for cerebrovascular events OR 1.22 (1.05–1.41) Morbidity risk for heart failure OR 1.32 (1.11–1.57) |
Abbreviations: CAD, coronary artery disease; CV, cardiovascular; HR, hazard ratio; IHD, ischemic heart disease; MACE, major adverse cardiovascular events; MI, myocardial infarction; OR, odds ratio; RR, relative risk; SMR, standardized mortality ratio. Values in brackets indicate 95% confidence intervals.